Literature DB >> 7643884

Virologic characteristics of subclinical and symptomatic genital herpes infections.

A Wald1, J Zeh, S Selke, R L Ashley, L Corey.   

Abstract

BACKGROUND: The frequency, pattern, and anatomical sites of subclinical shedding of herpes simplex virus (HSV) in the genital tract, along with factors that predict such shedding, have not been well characterized.
METHODS: We studied prospectively the clinical and virologic course of genital herpes in 110 women. The women kept symptom diaries and provided daily samples from the vulva, cervix, and rectum for viral culture.
RESULTS: During a median follow-up of 105 days, subclinical shedding of virus was identified in 36 of 65 women (55 percent) with HSV type 2 (HSV-2), in 16 of 31 women (52 percent) with HSV type 1 (HSV-1) and HSV-2, and in 4 of 14 women (29 percent) with only HSV-1. Among women with genital HSV-2 infection, subclinical shedding occurred on a mean of 2 percent of the days. The mean duration of viral shedding during subclinical episodes was 1.5 days, as compared with 1.8 days during symptomatic episodes. HSV was isolated from several sites in the genital tract and rectum in 17 percent of subclinical episodes and 22 percent of symptomatic episodes. Half the episodes of subclinical shedding of HSV occurred within seven days of a symptomatic recurrence. The risk of subclinical shedding increased with the frequency of symptomatic recurrences. Subclinical shedding was more frequent among women with more than 12 recurrences per year than among those with no symptomatic recurrences (odds ratio, 3.3; 95 percent confidence interval, 1.4 to 7.9); it was also more frequent among women who had recently acquired genital herpes (odds ratio for women with HSV acquired in the past year as compared with those who had had the infection for a year or more, 1.85; 95 percent confidence interval, 1.1 to 3.1).
CONCLUSIONS: Among women with a history of genital herpes infection, subclinical shedding of HSV is common and accounts for nearly one third of the total days of reactivation of HSV infection in the genital tract. Women with frequent symptomatic recurrences also have frequent subclinical shedding and may be at high risk for transmitting HSV.

Entities:  

Mesh:

Year:  1995        PMID: 7643884     DOI: 10.1056/NEJM199509213331205

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  135 in total

1.  Evaluation of an enzyme immunoassay system for measuring herpes simplex virus (HSV) type 1-specific and HSV type 2-specific IgG antibodies.

Authors:  H E Prince; C E Ernst; W R Hogrefe
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

2.  Novel approach for specific detection of herpes simplex virus type 1 and 2 antibodies and immunoglobulin G and M antibodies.

Authors:  B Ohana; M Lipson; N Vered; I Srugo; M Ahdut; A Morag
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

Review 3.  Improving the care of patients with genital herpes.

Authors:  S Drake; S Taylor; D Brown; D Pillay
Journal:  BMJ       Date:  2000-09-09

4.  Genital herpes, "the new paradigm".

Authors:  S Taylor; S Drake; D Pillay
Journal:  J Clin Pathol       Date:  1999-01       Impact factor: 3.411

5.  Herpes simplex virus type 2 serostatus is not associated with inflammatory or metabolic markers in antiretroviral therapy-treated HIV.

Authors:  Darrell H S Tan; Janet M Raboud; Leah Szadkowski; Tae Joon Yi; Brett Shannon; Rupert Kaul; W Conrad Liles; Sharon L Walmsley
Journal:  AIDS Res Hum Retroviruses       Date:  2014-12-17       Impact factor: 2.205

6.  Public Health Strategies to Prevent Genital Herpes: Where Do We Stand?

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.725

Review 7.  Using the evidence base on genital herpes: optimising the use of diagnostic tests and information provision.

Authors:  A Scoular
Journal:  Sex Transm Infect       Date:  2002-06       Impact factor: 3.519

8.  Type specific seroprevalence of HSV-1 and HSV-2 in four geographical regions of Poland.

Authors:  J S Smith; M Rosinska; A Trzcinska; J M Pimenta; B Litwinska; J Siennicka
Journal:  Sex Transm Infect       Date:  2006-04       Impact factor: 3.519

9.  Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.

Authors:  Sita Awasthi; John W Balliet; Jessica A Flynn; John M Lubinski; Carolyn E Shaw; Daniel J DiStefano; Michael Cai; Martha Brown; Judith F Smith; Rose Kowalski; Ryan Swoyer; Jennifer Galli; Victoria Copeland; Sandra Rios; Robert C Davidson; Maya Salnikova; Susan Kingsley; Janine Bryan; Danilo R Casimiro; Harvey M Friedman
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

10.  The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection.

Authors:  S L Rosenthal; G D Zimet; J S Leichliter; L R Stanberry; K H Fife; W Tu; D I Bernstein
Journal:  Sex Transm Infect       Date:  2006-04       Impact factor: 3.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.